Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis Takes Aim At Systemic Mastocytosis With Midostaurin

Executive Summary

Novartis AG's novel anticancer midostaurin is looking promising in the rare indication of advanced systemic mastocytosis given positive data from a pivotal Phase II study just published in the New England Journal of Medicine.

Advertisement

Related Content

Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
Novartis Oncology Strategy: Focus On The Microenvironment
High Hurdle For Novartis's New Oncology Division

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel